Improving Health Equity and Reducing Disparities in Pediatric and Adolescent/Young Adult Oncology: In Support of Clinical Practice Guidelines

Authors:
Justine M. Kahn Division of Pediatric Hematology/Oncology/Stem Cell Transplantation, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY

Search for other papers by Justine M. Kahn in
Current site
Google Scholar
PubMed
Close
 MD, MS
and
Melissa Beauchemin Division of Pediatric Hematology/Oncology/Stem Cell Transplantation, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY

Search for other papers by Melissa Beauchemin in
Current site
Google Scholar
PubMed
Close
 PhD, RN, CPNP
Restricted access

Despite extraordinary strides in cancer therapy over the past 30 years, racial/ethnic, socioeconomic, and age-related survival disparities persist. Hodgkin lymphoma offers an excellent paradigm to understand these disparities because successful approaches are well established in both the up-front and relapsed treatment settings. The following review, which accompanies the 2021 NCCN Guidelines for Pediatric Hodgkin Lymphoma, suggests that systemic inequities in cancer care disproportionately affect minority and low-income children, adolescents, and young adults, and directly contribute to observed disparities in cancer-related outcomes. It proposes that the first step toward reducing disparities is large-scale dissemination of guidelines, because equity is best achieved when treatment approaches are clear, comprehensive, and standardized across all clinical practice settings.

Submitted January 18, 2021; revision received March 30, 2021; accepted for publication April 20, 2021.

Disclosures: The authors have disclosed that they have not received any financial consideration from any person or organization to support the preparation, analysis, results, or discussion of this article.

Funding: This work is supported in part by the Lymphoma Research Foundation (J.M. Kahn) and by an NCI Training Program in Cancer-Related Population Sciences (NCI T32CA094061; M. Beauchemin).

Correspondence: Justine M. Kahn, MD, MS, Division of Pediatric Hematology/Oncology/Stem Cell Transplantation, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, 161 Fort Washington Avenue, IP7, New York, NY 10032. Email: jk2034@cumc.columbia.edu
  • Collapse
  • Expand
  • 1.

    Kahn JM, Keegan TH, Tao L, et al. Racial disparities in the survival of American children, adolescents, and young adults with acute lymphoblastic leukemia, acute myelogenous leukemia, and Hodgkin lymphoma. Cancer 2016;122:27232730.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER Research Data, 18 Registries, Nov 2019 Sub (2000–2017) - Linked To County Attributes - Time Dependent (1990–2017) Income/Rurality, 1969–2018 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2020, based on the November 2019 submission.

    • PubMed
    • Export Citation
  • 3.

    World Health Organization. Social determinants of health: key concepts. Accessed April 20, 2021. Available at: https://www.who.int/news-room/q-a-detail/social-determinants-of-health-key-concepts

    • PubMed
    • Export Citation
  • 4.

    Kahn JM, Kelly KM, Pei Q, et al. Survival by race and ethnicity in pediatric and adolescent patients with Hodgkin lymphoma: a Children’s Oncology Group study. J Clin Oncol 2019;37:30093017.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Friedman DL, Chen L, Wolden S, et al. Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk Hodgkin lymphoma: a report from the Children’s Oncology Group Study AHOD0031. J Clin Oncol 2014;32:36513658.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Keller FG, Castellino SM, Chen L, et al. Results of the AHOD0431 trial of response adapted therapy and a salvage strategy for limited stage, classical Hodgkin lymphoma: a report from the Children’s Oncology Group. Cancer 2018;124:32103219.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Diefenbach CS, Connors JM, Friedberg JW, et al. Hodgkin lymphoma: current status and clinical trial recommendations. J Natl Cancer Inst 2016;109:djw249.

  • 8.

    Kelly KM. Hodgkin lymphoma in children and adolescents: improving the therapeutic index. Hematology (Am Soc Hematol Educ Program) 2015;2015:514521.

  • 9.

    Kahn JM, Kelly KM. Adolescent and young adult Hodgkin lymphoma: raising the bar through collaborative science and multidisciplinary care. Pediatr Blood Cancer 2018;65:e27033.

  • 10.

    Keegan TH, Ries LA, Barr RD, et al. Comparison of cancer survival trends in the United States of adolescents and young adults with those in children and older adults. Cancer 2016;122:10091016.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Evens AM, Antillon M, Aschebrook-Kilfoy B, Chiu BCH. Racial disparities in Hodgkin's lymphoma: a comprehensive population-based analysis. Ann Oncol 2012;23:2128–2137.

    • Crossref
    • PubMed
    • Export Citation
  • 12.

    Keegan TH, Clarke CA, Chang ET, et al. Disparities in survival after Hodgkin lymphoma: a population-based study. Cancer Causes Control 2009;20:18811892.

  • 13.

    Institute of Medicine (US) Committee on Standards for Developing Trustworthy Clinical Practice Guidelines; Graham R, Mancher M, Miller Wolman D, et al, eds. Clinical Practice Guidelines We Can Trust. Washington, DC: National Academies Press; 2011.

    • PubMed
    • Export Citation
  • 14.

    Braveman P. What are health disparities and health equity? We need to be clear. Public Health Rep 2014;129(Suppl 2):58.

  • 15.

    Koh HK, Piotrowski JJ, Kumanyika S, et al. Healthy people: a 2020 vision for the social determinants approach. Health Educ Behav 2011;38:551557.

  • 16.

    Hiatt RA, Breen N. The social determinants of cancer: a challenge for transdisciplinary science. Am J Prev Med 2008;35(2 Suppl):S141150.

  • 17.

    Venkatapuram S, Marmot M. Epidemiology and social justice in light of social determinants of health research. Bioethics 2009;23:7989.

  • 18.

    Marmot MG, Bell R. Action on health disparities in the United States: commission on social determinants of health. JAMA 2009;301:11691171.

  • 19.

    Shavers VL, Fagan P, McDonald P. Health disparities across the cancer continuum. J Health Care Poor Underserved 2007;18(4 Suppl):15.

  • 20.

    Parsons HM, Harlan LC, Seibel NL, et al. Clinical trial participation and time to treatment among adolescents and young adults with cancer: does age at diagnosis or insurance make a difference? J Clin Oncol 2011;29:40454053.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Parsons HM, Maguire FB, Morris CR, et al. Impact of insurance type and timing of Medicaid enrollment on survival among adolescents and young adults with cancer. Pediatr Blood Cancer 2020;67:e28498.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Shariff-Marco S, Yang J, John EM, et al. Intersection of race/ethnicity and socioeconomic status in mortality after breast cancer. J Community Health 2015;40:12871299.

  • 23.

    Aristizabal P. Diverse populations and enrollment in pediatric cancer clinical trials: challenges and opportunities. Pediatr Blood Cancer 2020;67:e28296.

  • 24.

    Aristizabal P, Fuller S, Rivera R, et al. Improving pediatric cancer care disparities across the United States-Mexico border: lessons learned from a transcultural partnership between San Diego and Tijuana. Front Public Health 2015;3:159.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25.

    Keegan TH, DeRouen MC, Parsons HM, et al. Impact of treatment and insurance on socioeconomic disparities in survival after adolescent and young adult Hodgkin lymphoma: a population-based study. Cancer Epidemiol Biomarkers Prev 2016;25:264273.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    Rosenberg AR, Kroon L, Chen L, et al. Insurance status and risk of cancer mortality among adolescents and young adults. Cancer 2015;121:12791286.

  • 27.

    Wolfson J, Sun CL, Wyatt L, et al. Impact of treatment site on disparities in outcome among adolescent and young adults with Hodgkin lymphoma. Leukemia 2017;31:14501453.

  • 28.

    Hoppe RT, Advani RH, Ai WZ, et al. Hodgkin lymphoma, version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2020;18:755781.

  • 29.

    Grubb WR, Neboori HJ, Diaz AD, et al. Racial and ethnic disparities in the pediatric Hodgkin lymphoma population. Pediatr Blood Cancer 2016;63:428435.

  • 30.

    Wu J, Huang Y, Tergas AI, et al. The effect of guideline-concordant care in mitigating insurance status disparities in cervical cancer. Gynecol Oncol 2020;159:309316.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    Kelly KM, Sposto R, Hutchinson R, et al. BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children’s Oncology Group. Blood 2011;117:25962603.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32.

    Wright JD, Neugut AI, Ananth CV, et al. Deviations from guideline-based therapy for febrile neutropenia in cancer patients and their effect on outcomes. JAMA Intern Med 2013;173:559568.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Aapro M, Molassiotis A, Dicato M, et al. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol 2012;23:19861992.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34.

    Olver I. The MASCC Textbook of Cancer Supportive Care and Survivorship, 2nd ed. New York, NY: Springer; 2018.

  • 35.

    Patel P, Robinson PD, Orsey A, et al. Chemotherapy-induced nausea and vomiting prophylaxis: practice within the Children’s Oncology Group. Pediatr Blood Cancer 2016;63:887892.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36.

    Check DK, Reeder-Hayes KE, Zullig LL, et al. Examining racial variation in antiemetic use and post-chemotherapy health care utilization for nausea and vomiting among breast cancer patients. Support Care Cancer 2016;24:48394847.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37.

    Gomez DR, Liao K-P, Giordano S, et al. Adherence to national guidelines for antiemesis prophylaxis in patients undergoing chemotherapy for lung cancer: a population-based study. Cancer 2013;119:14281436.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 38.

    Beauchemin M, Sung L, Hershman DL, et al. Guideline concordant care for prevention of acute chemotherapy-induced nausea and vomiting in children, adolescents, and young adults. Support Care Cancer 2020;28:47614769.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39.

    Surbone A, Halpern MT. Unequal cancer survivorship care: addressing cultural and sociodemographic disparities in the clinic. Support Care Cancer 2016;24:48314833.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 40.

    Advani PS, Ying J, Theriault R, et al. Ethnic disparities in adherence to breast cancer survivorship surveillance care. Cancer 2014;120:894900.

  • 41.

    Mobley EM, Moke DJ, Milam J., et al. AHRQ Comparative Effectiveness Technical Briefs. Disparities and Barriers to Pediatric Cancer Survivorship Care. Rockville, MD: Agency for Healthcare Research and Quality; 2021

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 42.

    Castellino SM, Parsons SK, Kelly KM. Closing the survivorship gap in children and adolescents with Hodgkin lymphoma. Br J Haematol 2019;187:573587.

  • 43.

    Faulk KE, Anderson-Mellies A, Cockburn M, et al. Assessment of enrollment characteristics for Children’s Oncology Group (COG) upfront therapeutic clinical trials 2004-2015. PLoS One 2020;15:e0230824.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 44.

    Keegan THM, Parsons HM. Adolescent angst: enrollment on clinical trials. Hematology (Am Soc Hematol Educ Program) 2018;2018:154160.

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 3638 1256 118
PDF Downloads 1858 406 36
EPUB Downloads 0 0 0